Major stock indexes declined Thursday as investors digested several big tech earnings reports and awaited more after the ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

"It was during my hysterectomy surgery that I realised something had to change. I was asked if I had a will and needed to ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Meghan Trainor showed off her flat abs in a mirror selfie with coach Bella Maher after the pop star went through a weight ...

A groundbreaking study has compared the three top weight loss medications on the market, which has produced some surprising ...

Discover Eli Lilly’s Q3 2025 earnings highlights: record 54% revenue growth, new product approvals, raised guidance, and global expansion.

Por TOM MURPHYEl mercado de tratamientos para la obesidad y la diabetes sigue siendo extremadamente activo, canalizando miles de millones de dólares en ventas para Eli Lilly y alimentando una ...

LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive ...